Investigation of muscle disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 60, Issue 3, 1996, Pages 256-274

  Mastaglia, F L ^a   Laing, N G ^a  

^a PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GEMFIBROZIL; PENICILLAMINE; SUXAMETHONIUM; UNINDEXED DRUG; ZIDOVUDINE;

ELECTRODIAGNOSIS; MITOCHONDRIAL MYOPATHY; MOLECULAR BIOLOGY; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE NECROSIS; MUSCULAR DYSTROPHY; MYALGIA; MYOSITIS; MYOTONIA; PRIORITY JOURNAL; REVIEW;

EID: 0029897708     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.60.3.256     Document Type: Review

References (182)

1. Neuromuscular disorders: gene location. Neuromuscul Disord 1995;6:I-III.
2. Mitochondrial encephalomyopathies: gene mutation. Neuromuscul Disord 1995;6:V-VI.
3. Argov Z, Mastaglia FL. Drug-induced neuromuscular disorders in man. In: Walton JN, Karpati G, Hilton-Jones D, eds. Disorders of voluntary muscle. 6th ed. Edinburgh: Churchill Livingstone, 1994:898-1029.
4. Lane RJM, Mastaglia FL. Drug-induced myopathies in man. Lancet 1978;ii:562-5.
5. Mastaglia FL. Toxic myopathies. In: Rowland LP, DiMauro S, eds. Handbook of clinical neurology. Amsterdam: Elsevier, 1992:595-622.
6. Suarez GA, Kelly JJ. The dropped head syndrome. Neurology 1992;42:1625-7.
7. Garlepp MJ, Mastaglia FL. Inclusion body myositis. J Neurol Neurosurg Psychiatry 1996;60:251-5.
8. Harvey JM, Mastaglia FL, Zilko PJ, Ojeda VJ, Cheah PS. Scleromyxedema and inflammatory myopathy: a clinicopathological study of three patients. Aust NZ J Med 1986;16:329-35.
9. Griggs RC, Mendell JR, Miller RG. Evaluation and treatment of myopathies. Contemporary neurology series. Philadelphia: FA Davis, 1995.
10. Sunohara N, Takagi A, Nonaka I, Sugita H, Satoyoshi E. Idiopathic hyperCKemia. Neurology 1984;34:544-7.
11. Tien I, DiMauro S, Rowland LP. Myoglobinuria. In: Rowland LP, DiMauro S, eds. Handbook of clinical neurology. Amsterdam: Elsevier, 1992:553-93.
12. Kagen LJ. Myoglobinaemia in inflammatory myopathies. JAMA 1977;237:1448-52.
13. Moxley RT. Metabolic and endocrine myopathies. In: Walton JN, Karpati G, Hilton-Jones D, eds. Disorders of voluntary muscle. 6th ed. Edinburgh: Churchill Livingstone, 1994:647-716.
14. 31PMRS) in neuromuscular disorders. Ann Neurol 1991;30:90-7.
15. Moussavi RS, Carson PJ, Boska MD, Weiner MW, Miller RG. Nonmetabolic fatigue in exercising human muscle. Neurology 1989;39:1222-6.
16. McKeran RO, Hallidan D, Purkiss P, Royston P. 3-methylhistidine excretion as an index of myofibrillar protein catabolism in neuromuscular disease. J Neurol Neurosurg Psychiatry 1979;42:536-41.
17. Ohkoshi N, Yoshizawa T, Mizusawa H, et al. Malignant hyperthermia in a patient with Becker muscular dystrophy: dystrophin analysis and caffeine contracture study. Neuromusc Disord 1995;5:53-8.
18. Fawcett PRW, Barwick DD. The clinical neurophysiology of neuromuscular disease. In: Walton JN, Karpati G, Hilton-Jones D, eds. Disorders of voluntary muscle. 6th ed. Edinburgh: Churchill Livingstone, 1994:1033-104.
19. Eisen A, Berry K, Gibson G. Inclusion body myositis: myopathy or neuropathy? Neurology 1983;33:1109-14.
20. Grindrod S, Tofts P, Edwards R. Investigation of human skeletal muscle structure and composition by X-ray computerised tomography. Eur J Clin Invest 1983; 13:465-8.
21. Kiers L. Diabetic muscle infarction: magnetic resonance imaging (MRI) avoids the need for biopsy. Muscle Nerve 1995;18:129-30.
22. De Visser M, Verbeeten B. Computed tomography of the skeletal musculature in Becker-type muscular dystrophy and benign infantile spinal muscular atrophy. Muscle Nerve 1985;8:435-44.
23. Pamphlett R. Muscle biopsy. In: Mastaglia FL, Walton JN, eds. Skeletal muscle pathology. 2nd ed. Edinburgh: Churchill Livingstone, 1992:95-121.
24. Bönnemann CG, Modi R, Noguchi S, et al. β-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of sarcoglycan complex. Nature Genet 1995;11:266-73.
25. Beggs AH, Kunkel LM. Improved diagnosis of Duchenne/Becker muscular dystrophy. J Clin Invest 1990;85:613-9.
26. Hoffman EP, Fischbeck KH, Brown RH, et al. Characterization of dystropin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 1988;318:1363-8.
27. Hoffman EP, Kunkel LM, Angelini C, Clarke A, Johnson M, Harris JB. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology 1989;39: 1011-7.
28. Piccolo F, Roberds SL, Jeanpierre M, et al. Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nature Genet 1995;10:243-5.
29. Malhotra SB, Hart KA, Klamut HJ, et al. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science 1988;242:755-9.
30. Chelly J, Gilgenkrantz H, Lambert M, et al. Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. Cell 1990;63:1239-48.
31. Morisaki H, Morisaki T, Newby LK, Holmes EW. Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect. J Clin Invest 1993;91: 2275-80.
32. Collins FS. Positional cloning moves from perditional to traditional. Nature Genet 1995;9:347-50.
33. Noguchi S, McNally EM, Othmane KB, et al. Mutations in the dystrophin-associated protein γ-sarcoglycan in chromosome 13 muscular dystrophy. Science 1995;270: 819-22.
34. Lim LE, Duclos F, Broux O, et al. β-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nature Genet 1995;11:257-65.
35. Evans MI, Greb A, Kunkel LM, et al. In utero fetal muscle biopsy for the diagnosis of Duchenne muscular dystrophy. Am J Obstet Gynecol 1991;165:728-32.
36. Bradley DM, Parsons EP, Clarke AJ. Experience with screening newborns for Duchenne muscular dystrophy in Wales. BMJ 1993;306:357-60.
37. Greenberg CR, Jacobs HK, Halliday W, Wrogmann K. Three year's experience with neonatal screening for Duchenne/Becker muscular dystrophy: gene analysis, gene expression and phenotype prediction. Am J Med Genet 1991;39:68-75.
38. Ptacek LJ, Tawil R, Griggs RC, et al. Dihydropyridine receptor mutations cause hypokalaemic periodic paralysis. Cell 1994;77:863-8.
39. Mullis KB, Faloona FA. Specific synthesis of DNA in vitro via a polymerase-catalysed chain reaction. Meth Enzymol 1987;155:335-50.
40. Roberts RG, Bentley DR, Barby TFM, et al. Direct diagnosis of carriers of Duchenne and Becker muscular dystrophy by amplification of lymphocyte RNA. Lancet 1990; 336:1523-6.
41. Zeviani M, Amati P, Bresolin N, et al. Rapid detection of the A-G mutation of mtDNA in Italian families with myoclonus epilepsy and ragged red fibers. Am J Hum Genet 1991;48:203-11.
42. Shelbourne P, Winquist R, Kunert E, et al. Unstable DNA may be responsible for the incomplete penetrance of the myotonic dystrophy phenotype. Human Molecular Genetics 1992;1:467-73.
43. Abbs S, Yau SC, Clark S, Mathew CG, Bobrow M. A convenient multiplex PCR system for the detection of dystrophin gene deletions: a comparative analysis with cDNA hybridisation shows mistypings by both methods. J Med Genet 1991;28:304-11.
44. Chamberlain JS, Gibbs RA, Ranier JE, Nguyen PN, Caskey CT. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res 1988;16:11141-56.
45. Chamberlain JS, Gibbs RA, Ranier JE, Caskey CT. Multiplex PCR for the diagnosis of Duchenne muscular dystrophy. In Innis M, Gelfland D, Sninsky J, White T, eds. PCR protocols: a guide to methods and applications. San Diego: Academic Press, 1990:272-81.
46. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-65.
47. Rodrigues NR, Owen N, Talbot K, Ignatius J, Dubowitz V, Davies KE. Deletions in the survival motor neuron gene on 5q13 in autosomal recessive spinal muscular atrophy. Human Molecular Genetics 1995;4:631-4.
48. Lehmann-Horn F, Rüdel R. Hereditary nondystrophic myotonias and periodic paralyses. Curr Opin Neurol Neurosurg 1995;8:402-10.
49. Wallace DC: Mitochondrial DNA mutations and neuromuscular disease. TIGS 1989;5:9-13.
50. Suomalainen A, Kaukonen J, Amati P, et al. An autosomal locus predisposing to deletions of mitochondrial DNA. Nature Genet 1995;5:146-51.
51. Forrest S, Cotton R, Landegren U, Southern E. How to find all those mutations. Nature Genet 1995;10:375-6.
52. Grompe M. The rapid detection of unknown mutations in nucleic acids. Nature Genet 1993;5:111-7.
53. Liu Q, Sommer SS. Restriction endonuclease fingerprinting (REF): a sensitive method for screening for mutations in long, contiguous segments of DNA. Biotechniques 1995;18:470-7.
54. Sarkar G, Yoon H-S, Sommer SS. Dideoxy fingerprinting (ddf): a rapid and efficient screen for the presence of mutations. Genomics 1992;13:441-3.
55. Mashal RD, Koontz J, Sklar J. Detection of mutations by cleavage of DNA heteroduplexes with bacteriophage resolvases. Nature Genet 1995;9:177-83.
56. Youil R, Kemper BW, Cotton RGH. Screening for mutations by enzyme mismatch cleavage with T4 endonuclease VII. Proc Natl Acad Sci USA 1995;92:87-91.
57. Wilton SD, Johnsen RD, Pedretti JR, Laing NG. Two distinct mutations in a single dystrophin gene: identification of an altered splice-site as the primary Becker muscular dystrophy mutation. Am J Med Genet 1993;46:563-9.
58. Wilton SD, Chandler DC, Kakulas BA, Laing NG: Identification of a point mutation and germinal mosaicism in a Duchenne muscular dystrophy family. Human Mutation 1994;3:133-40.
59. Chelly J, Gilgenkrantz H, Hugnot JP, et al. Illegitimate transcription: application to the analysis of truncated transcripts of the dystrophin gene in nonmuscle cultured cells from Duchenne and Becker patients. J Clin Invest 1991;88:1161-6.
60. Wallace DC: Mitochondrial diseases: genotype versus phenotype. TIGS 1993;9:128-33.
61. Prior TW, Papp AC, Snyder PJ, et al. A missense mutation in the dystrophin gene in a Duchenne muscular dystrophy patient. Nature Genet 1993;4:357-60.
62. Wang J, Zhou J, Todorovic SM, et al. Molecular genetic and genetic correlations in sodium channelopathies: lack of founder effect and evidence for a second gene. Am J Hum Genet 1993;52:1074-84.
63. Ohno K, Hutchinson DO, Milone M, et al. Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the ε-subunit. Proc Natl Acad Sci USA 1995;92:758-62.
64. Bejaoui K, Hirabayashi K, Hentati F, et al. Linkage of Miyoshi myopathy (distal autosomal recessive muscular dystrophy) locus to chromosome 2p12-14. Neurology 1995;45:768-72.
65. Laing NG, Laing BA, Meredith C, et al. Autosomal dominant distal myopathy: linkage to chromosome 14. Am J Hum Genet 1995;56:422-7.
66. Speer MC, Yamaoka LH, Gilchrist JH, et al. Confirmation of genetic heterogeneity in limb-girdle muscular dystrophy: linkage of an autosomal dominant form to chromosome 5q. Am J Hum Genet 1992;50: 1211-7.
67. Yamaoka LH, Westbrook CA, Speer MC, et al. Development of a microsatellite genetic map spanning 5q31-33 and subsequent placement of the LGMD1A locus between D5S178 and IL9. Neuromuscul Disord 1994;4: 471-5.
68. Janssen EAM, Hensels GW, van Oost BA, et al. The gene for X-linked myotubular myopathy is located in an 8 Mb region at the border of Xq27.3 and Xq28. Neuromuscul Disord 1994;4:455-61.
69. Brais B, Xie Y-G, Sanson M, et al. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac α and β myosin heavy chain genes on chromosome 14q11.2-q13. Human Molecular Genetics 1995;4:429-34.
70. Wallgren-Pettersson C, Avela K, Marchand S, et al. A gene for autosomal recessive nemaline myopathy assigned to chromosome 2q by linkage analysis. Neuromuscul Disord 1995;5:441-3.
71. McCarthy TV, Healy JMS, Heffron JJA, et al. Localization of malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343:562-4.
72. Deufel T, Golla A, Iles D, et al. Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Am J Hum Genet 1992;50:1151-61.
73. Levitt RC, Nouri N, Jedlicka AE, et al. Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics 1991;11:543-7.
74. MacLennan DH. Discordance between phenotype and genotype in malignant hyperthermia. Curr Opin Neurol Neurosurg 1995;8:397-401.
75. Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993;329:1982-7.
76. Roest PAM, Roberts RG, Sugino S, van Ommen G-JB, den Dunnen JT. Protein truncation test (PTT) for rapid detection of translation-terminating mutations. Human Molecular Genetics 1993;2:1719-21.
77. Heim RA, Silverman LM, Kam-Morgan LNW, Luce MC. Screening for truncated NF1 proteins. Nature Genet 1994;8:318-9.
78. Heim RA, Kam-Morgan LNW, Binnie CG, et al. Distribution of 13 truncating mutations in the neurofibromatosis 1 gene. Human Molecular Genetics 1995;4: 975-81.
79. Campbell KP. Adhalin gene mutations and autosomal recessive limb-girdle muscular dystrophy. Ann Neurol 1995;38:353-4.
80. Byrne E. Mitochondrial DNA abnormalities in human disease. Med J Aust 1991;154:646-7.
81. Kakulas BA. The spectrum of dystrophinopathies. In: Lane RJM, ed. Handbook of muscle disease. New York: Marcell Dekker 1996 (in press).
82. Van Ommen GJB, Scheuerbrandt G. Neonatal screening for muscular dystrophy. Consensus recommendation of the 14th workshop sponsored by the European Neuromuscular Center (ENMC). Neuromuscul Disord 1993;3: 231-9.
83. Muntoni F, Mateddu A, Cianchetti C, et al. Dystrophin analysis using a panel of anti-dystrophin antibodies in Duchenne and Becker muscular dystrophy. J Neurol Neurosurg Psychiatry 1993;56:26-31.
84. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50: 509-17.
85. den Dunnen J, Bakker E, Klein-Breteler E, Pearson P, van Ommen G. Direct detection of more than 50% of the Duchenne muscular dystrophy mutations by field inversion gels. Nature 1987;329:640-2.
86. Laing NG, Mears ME, Thomas HE, et al. Differentiation of Becker muscular dystrophy from limb-girdle muscular dystrophy and Kugelberg-Welander disease using a cDNA probe. Med J Aust 1990;152:270-1.
87. Lum PW, Cumming WJK, Kingston H, et al. DNA probes in differential diagnosis of Becker muscular dystrophy and spinal muscular atrophy. Lancet 1989;i: 46-7.
88. Norman A, Thomas N, Coakley J, Harper P. Distinction of Becker from limb-girdle muscular dystrophy by means of dystrophin cDNA probes. Lancet 1989;i:466-8.
89. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed by the polymerase chain reaction. Am J Hum Genet 1989;44:388-96.
90. Hejtmancik J, Harris S, Tsao C, Ward P, Caskey C. Carrier diagnosis of Duchenne muscular dystrophy using restriction fragment length polymorphisms. Neurology 1986;36:1553-62.
91. Laing NG, Siddique T, Bartlett RJ, et al. Duchenne muscular dystrophy: detection of deletion carriers by spectrophotometric densitometry. Clin Genet 1989;35: 393-8.
92. Mao Y, Cremer M. Detection of Duchenne muscular dystrophy carriers by dosage analysis using the DMD cDNA clone 8. Hum Genet 1989;81:193-5.
93. Bartlett RJ, Pericak-Vance MA, Lanman JT, et al. Prenatal detection of an inherited Duchenne muscular dystrophy deletion allele. Neurology 1987;37:355-6.
94. Abbs S, Bobrow M. Analysis of quantitative PCR for the diagnosis of deletion and duplication carriers in the dystrophin gene. J Med Genet 1992;29:191-6.
95. Ioannou P, Christopoulos G, Panayides K, Kleanthous M, Middleton L. Detection of Duchenne and Becker muscular dystrophy carriers by quantitative multiplex polymerase chain reaction analysis. Neurology 1992;42: 1783-90.
96. Beggs AH, Hoffman EP, Snyder JR, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 1991;49:54-7.
97. Sunohara N, Arahata K, Hoffman EP, et al. Quadriceps myopathy: forme fruste of Becker muscular dystrophy. Ann Neurol 1990;28:634-9.
98. Gospe SM, Lazaro RP, Lava NS, Grootscholten BS, Scott MO, Fischbeck KH. Familial X-linked myalgia and cramps: a non-progressive myopathy associated with a deletion in the dystrophin gene. Neurology 1989;39:1277-80.
99. Malapert D, Recan D, Leturcq F, Degos JD, Gherardi RK. Sporadic lower limb hypertrophy and exercise induced myalgia in a woman with dystrophin gene deletion. J Neurol Neurosurg Psychiatry 1995;59:552-4.
100. Servidei S, Manfredi G, Mirabella M, et al. Familial hyperCKemia can be a variant of Becker muscular dystrophy. Neurology 1993;43:A293.
101. Piccolo G, Azan G, Tonin P, et al. Dilated cardiomyopathy requiring cardiac transplantation as initial manifestation of Xp21 Becker type muscular dystrophy. Neuromuscul Disord 1994;4:143-6.
102. Yoshida K, Ikeda S-I, Nakamura A, et al. Molecular analysis of the Duchenne muscular dystrophy gene in patients with Becker muscular dystrophy presenting with dilated cardiomyopathy. Muscle Nerve 1993;16:1161-6.
103. Beckmann JS, Richard I, Hillaire D, et al. A gene for limb-girdle muscular dystrophy maps to chromosome 15 by linkage. C R Acad Sci (Paris) 1991;312:141-8.
104. Fougerousse F, Broux O, Richard I, et al. Mapping of a chromosome 15 region involved in limb girdle muscular dystrophy. Human Molecular Genetics 1994;3:285-93.
105. Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995;81:27-40.
106. Matsumura K, Nonaka I, Campbell KP. Abnormal expression of dystrophin-associated proteins in Fukuyama-type congenital muscular dystrophy. Lancet 1993;341:521-2.
107. Tome FMS, Evangelista T, Leclerc A, et al. Congenital muscular dystrophy with merosin deficiency. C R Acad Sci (Paris) 1994;317:351-7.
108. Bashir R, Strachan T, Keers S, et al. A gene for autosomal recessive limb-girdle muscular dystrophy, maps to chromosome 2p. Human Molecular Genetics 1994;3:455-7.
109. Speer MC, Yamaoka LH, Gilchrist JM, et al. Evidence for genetic heterogeneity in the dominant form of limb-girdle muscular dystrophy. Am J Hum Genet 1993;53:A1082.
110. Matsumura K, Tome FMS, Collin H, et al. Deficiency of the 50K dystrophin-associated glycoprotein in severe childhood autosomal recessive muscular dystrophy. Nature 1992;359:320-2.
111. Ljunggren A, Duggan D, McNally E, et al. Primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin. Ann Neurol 1995;38: 367-72.
112. Roberds SL, Leturq F, Allamand V, et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 1994;78:625-33.
113. Arahata K, Ishii H, Hayashi YK. Congenital muscular dystrophies. Curr Opin Neurol Neurosurg 1995;8:385-90.
114. Helbling-Leclerc A, Zhang X, Topaloglu H, et al. Mutations in the laminin a2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nature Genet 1995;11:216-8.
115. Toda T, Segawa M, Nomura Y, et al. Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31-33. Nature Genet 1993;5:283-6.
116. Toda T, Yoshioka M, Nakahori Y, et al. Genetic identity of Fukuyama-type congenital muscular dystrophy and Walker-Warburg syndrome. Ann Neurol 1995;37: 99-101.
117. Wijmenga C, Frants RR, Brouwer OF, Moerer P, Weber JL, Padberg GW. Localisation of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet 1990;336:651-3.
118. Wijmenga C, Brouwer OF, Padberg GW, Frants RR. Transmission of de novo mutation associated with facioscapulohumeral muscular dystrophy. Lancet 1992; 340:985-6.
119. Wijmenga C, Hewitt JE, Sandkuijl LA, et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nature Genet 1992;2:26-30.
120. Weiffenbach B, Dubois J, Storvick D, et al. Mapping the facioscapulohumeral muscular dystrophy gene is complicated by chromosome 4q35 recombination events. Nature Genet 1993;4:165-9.
121. Gilbert JR, Stajich JM, Wall S, et al. Evidence for heterogeneity in facioscapulohumeral muscular dystrophy (FSHD). Am J Hum Genet 1993;53:401-8.
122. Bione S, Maestrini E, Rivella S, et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nature Genet 1994,8:323-7.
123. Laing NG. Inherited disorders of contractile proteins in skeletal and cardiac muscle. Curr Opin Neurol Neurosurg 1995;8:391-6.
124. Hageman ATM, Gabreëls, Liem KD, Renkawek K, Boon JM. Congenital myotonic dystrophy; a report on thirteen cases and a review of the literature. J Neurol Sci 1993;115:95-101.
125. Harper PS. Myotonic dystrophy. Major problems in neurology. Vol 9. Philadelphia: WB Saunders, 1979.
126. Serisier DE, Mastaglia FL, Gibson GJ. Respiratory muscle function and ventilatory control I in patients with motor neurone disease, II in patients with myotonic dystrophy. Q J Med 1982;202:205-26.
127. Viitasalo MT, Kala R, Karli P, Eisalo A. Ambulatory electro-cardiographic recording in mild or moderate myotonic dystrophy and myotonia congenita (Thomsen's disease). J Neurol Sci 1983;62:181-90.
128. Winters SJ, Schreiner B, Griggs RC, Rowley P, Nanda NC. Familial mitral valve prolapse and myotonic dystrophy. Ann Intern Med 1976;85:19-22.
129. Buxton J, Shelbourne P, Davies J, et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nature 1992;355:547-8.
130. Fu Y-H, Pizzuti A, Fenwick Jr RG, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992;255:1256-8.
131. Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 1992;255: 1253-5.
132. Reardon W, Harley HG, Brook JD, et al. Minimal expression of myotonic dystrophy: a clinical and molecular analysis. J Med Genet 1992;29:770-3.
133. Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic myopathy. Neurology 1994;44:1448-52.
134. Thornton CA, Griggs RC, Moxley RT. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994;35:269-72.
135. Sun SF, Streib EW. Autosomal recessive generalised myotonia. Muscle Nerve 1983;6:143-7.
136. Becker PE. Syndromes associated with myotonia: clinical-genetic classification. In: Rowland LP, ed. Pathogenesis of human muscular dystrophies. Amsterdam: Excerpta Medica 1977:699-705.
137. Hudson AJ, Ebers GC, Bulman DE. Brain 1995;118: 547-63.
138. Ricker K, Moxley RT, Heine R, Lehmann-Horn F. Myotonia fluctuans. A third type of muscle sodium channel disease. Arch Neurol 1994;51:1095-102.
139. Campa JA, Sanders DB. Familial hypokalaemic periodic paralysis. Arch Neurol 1974;31:110-5.
140. McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve 1986;9:704-10.
141. Kantola IM, Tarssanen LT. Diagnosis of familial hypokalemic periodic paralysis: role of the potassium exercise test. Neurology 1992;42:2158-61.
142. Elbaz A, Vale-Santos J, Jurkat-Rott K, et al. Hypokalaemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 Caucasian families. Am J Hum Genet 1995;56:374-80.
143. Jurkat-Rott K, Lehmann-Horn F, Elbaz A, et al. A calcium channel mutation causing hypokalaemic periodic paralysis. Human Molecular Genetics 1994;3:1415-9.
144. Ptacek LJ, Trimmer JS, Agnew WS, Roberts JW, Petajan JH, Leppert M. Paramyotonia congenita and hyperkalaemic periodic paralysis map to the same sodium channel gene locus. Am J Hum Genet 1991;49: 851-4.
145. + channel α- subunit in hyperkalaemic periodic paralysis. Nature 1991;354:387-9.
146. Baquero JL, Ayala RA, Wang J, et al. Hyperkalemic periodic paralysis with cardiac dysrhythmia: a novel sodium channel mutation? Ann Neurol 1995;37:408-11.
147. Tawil R, Ptacek LJ, Pavlakis SG, et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 1994;35:326-30.
148. Fardeau M. Congenital myopathies. In: Mastaglia FL, Walton JN, eds. Skeletal muscle pathology. 2nd ed. Edinburgh: Churchill-Livingstone, 1992:237-81.
149. Laing NG, Majda BT, Akkari PA, et al. Assignment of a gene (NEM1) for autosomal dominant nemaline myopathy to chromosome 1. Am J Hum Genet 1992;50: 576-83.
150. Laing NG, Wilton SD, Akkari PA, et al. A mutation in the α-tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy. Nature Genet 1995;9: 75-9.
151. Beggs AH, Byers TJ, Knoll JHM, Boyce FM, Bruns GAP, Kunkel L. Cloning and characterization of two human skeletal muscle alpha-actinin genes on chromosome one and eleven. J Biol Chem 1992;267:9281-8.
152. Haan EA, Freemantle CJ, McCure JA, Friend KL, Mulley JC. Assignment of the gene for central core disease to chromosome 19. Hum Genet 1990;86:187-90.
153. Kausch K, Lehmann-Horn F, Janka M, Wieringa B, Grimm T, Muller CR. Evidence for linkage of the central core disease locus to the proximal long arm of human chromosome 19. Genomics 1991;10:765-9.
154. Quane KA, Healy JMS, Keating KE, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nature Genet 1983;5:51-5.
155. Quane KA, Keating KE, Healy JMS, et al. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel tyr-ser mutation in a pedigree with associated central cores. Genomics 1994;23:236-9.
156. Zhang Y, Chen HS, Khanna VK, et al. A mutation in the human ryanodine receptor gene associated with central core disease. Nature Genet 1993;5:46-50.
157. Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988;331:717-9.
158. Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutations associated with Leber's hereditary optic neuropathy. Science 1988;242:1427-30.
159. Jackson MJ, Schaefer JA, Johnson MA, Morris AAM, Turnbull DM, Bindoff LA. Presentation and clinical investigation of mitochondrial respiratory chain disease. Brain 1995;118:339-57.
160. Johns DR. Mitochondrial DNA and disease. New Engl J Med 1995;333:638-44.
161. Morgan-Hughes JA. Mitochondrial diseases. In: Mastaglia FL, Walton JN, eds. Skeletal muscle pathology. 2nd ed. Edinburgh: Churchill-Livingstone, 1992: 367-424.
162. DiMauro S, Moraes CT. Mitochondrial encephalomyopathies. Arch Neurol 1993;50:1197-208.
163. Mechler F, Johnson MA, Mastaglia FL, et al. Mitochondrial myopathies. A clinico-pathological study of cases with and without extra-ocular muscle involvement. Aust NZ J Med 1986;16:185-92.
164. Zeviani M, Moraes CT, DiMauro S, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988;38:1339-46.
165. Zeviani M, Servidei S, Gellera C, Bertini E, DiMauro S, DiDonato S. An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature 1989;339:309-11.
166. Mechler F, Fawcett PRW, Mastaglia FL, Hudgson P. Mitochondrial myopathy: a study of clinically affected and asymptomatic members of a six-generation family. J Neurol Sci 1981;50:191-200.
167. Ozawa M, Goto Y-I, Sakuta R, Tanno Y, Tsuji S, Nonaka I. The 8,344 mutation in mitochondrial DNA: a comparison between the proportion of mutant DNA and clinicopathological findings. Neuromusc Disord 1995;5:483-8.
168. Suomalainen A, Ciafaloni E, Koga Y, Peltonen L, Dimauro S, Schon EA. Use of single strand conformation polymorphism analysis to detect point mutations in human mitochondrial DNA. J Neurol Sci 1992;111: 222-6.
169. Kawai H, Akaike M, Yokoi K, et al. Mitochondrial encephalomyopathy with autosomal dominant inheritance: a clinical and genetic entity of mitochondrial diseases. Muscle Nerve 1995;18:753-60.
170. Cheng S, Higuchi R, Stoneking M. Complete mitochondrial genome amplification. Nature Genet 1994;7: 350-1.
171. Howell N, Kubacka I, Halvorson S, Howell B, McCullough DA, Mackey D. Phylogenetic analysis of the mitochondrial genomes from Leber hereditary optic neuropathy pedigrees. Genetics 1995;140:285-302.
172. Lertrit P, Kapsa RMI, Jean-Francois MJB, et al. Mitochondrial DNA polymorphism in disease: a possible contributor to respiratory dysfunction. Human Molecular Genetics 1994;3:1973-81.
173. DiMauro S, Tonin P, Servidei S. Metabolic myopathies. In: Rowland LP, DiMauro S, eds. Handbook of clinical neurology. Amsterdam: Elsevier, 1992:479-526.
174. MacLennan DH, Duff C, Zorzato F, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990;343:559-61.
175. 2+ release channel (ryanodine receptor) of skeletal muscle. J Biol Chem 1990;265:2244-56.
176. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208.
177. Karpati G, Carpenter S. Pathology of the inflammatory myopathies. In: Mastaglia FL, ed. Inflammatory myopathies. Bailliere's Clinical Neurology 1993;2/3: 527-56.
178. Bernstein RM. Autoantibodies in myositis. In: Mastaglia FL, ed. Inflammatory myopathies. Bailliere's Clinical Neurology 1993;2/3:599-615.
179. Dalakas MC, Pezeshpour GH. Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol 1988;23(suppl):S38-S48.
180. Mastaglia FL, Ojeda VJ. Inflammatory myopathies: Part I. Ann Neurol 1985;17:215-27.
181. Mastaglia FL, Laing BA, Zilko P. Treatment of inflammatory myopathies. In: Mastaglia FL, ed. Inflammatory myopathies. Bailliere's Clinical Neurology 1993;2/3: 717-40.
182. Woolf RE, Baethge BA. Interleukin-1a, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arth Rheum 1990;33:1007-14.